CRIS, US2312694084

Curis stock: Q3 results mark latest emavusertib update

Published on 11/17/2026 at 22:04 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Curis stock gets a quarterly update as the company reports results for the period ended September 30. Emavusertib remains its development focus.

Quarterly update and trial focus

  • Curis announced its third-quarter results on November 12, covering the period ended September 30, 2026.
  • The filing identifies CRIS as listed on the Nasdaq Capital Market and includes the press release as Exhibit 99.1.
CRIS, US2312694084, Illustration mit AI erstellt.

Curis reported its third-quarter financial and operating results on November 12, 2026, for the three months ended September 30. The announcement was filed with the U.S. Securities and Exchange Commission in a Form 8-K, which lists the press release as Exhibit 99.1.

The filing identifies Curis as a biotechnology company with common stock trading under CRIS on the Nasdaq Capital Market. The company remains focused on the development of emavusertib, its clinical-stage program.

Disclosure confirms Nasdaq listing

For investors, the filing links the quarterly update to Curis's current corporate and listing status. It also provides the formal record of the November 12 announcement and distinguishes the reporting date from the September 30 financial period.

The SEC filing is the company disclosure covering the quarterly results.

Curis, Inc.

  • Company: Curis, Inc.
  • ISIN: US2312694084
  • Ticker: CRIS
  • Exchange: Nasdaq Capital Market
  • Reporting period: Third quarter ended September 30, 2026
  • Announcement date: November 12, 2026

U.S. equity market developments are covered in the S&P 500 market reports.

More news and analyses on Curis stock

Disclaimer...
en | US2312694084 | CRIS | boerse | 70528678 | bgmi